🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The Runner-up of the faculty #3MT finals is Annie Luo for her presentation "Bistriazine, a novel antimalarial" 👏👏👏

And the 1st place goes to... Shin Liau for her presentation "Focus on Frailty". Shin will represent the faculty at the Monash-wide #3MT finals in August. Congratulations!

Kickstarting @ICPE22 with the first pre-conference session on a toolbox for professional empowerment in pharmacoepi!!

Fabulous presentation at #ICPE22 by Dr Jenni Ilomaki on the 4C4D Study: Four Continents for #Dementia 👏 CMUS Monash Institute of Pharmaceutical Sciences Monash University

George Tan about to share his findings on the use of RWD for drug repurposing during lunch break International Society for Pharmacoepidemiology #icpe2022 CMUS Carl Kirkpatrick Erica Sloan

How did COVID-19 affect prescription opioid use in Australia? Spotlight poster presented by Monica Jung International Society for Pharmacoepidemiology #ICPE22 Suzanne Nielsen PhD MPS @MonashDFI CMUS Monash Addiction Research Centre

How are symptomatic and preventive medicines used in Australian and Japanese nursing homes by #frailty status? Check out this poster by Shin Liau presented International Society for Pharmacoepidemiology #ICPE22 CMUS CRE_Frailty

New Drug Discovery Today review from CMUS shows big data can be used to identify existing medication for 'drug repurposing'. George Tan Cancer Neural-Immune Lab Pete Lambert Carl Kirkpatrick Jenni Ilomaki monash.edu/pharm/about/ne…

Our latest #international #agedcare #research: doi.org/10.1007/s40520… 🇬🇸 #Australia: Ratio of symptomatic to preventive #medication use was higher with #frailty but lower with #age 🇯🇵 #Japan: Ratio remained consistent across #age & #frailty groups

Targeting COX2 to improve insulin resistance? We conducted an epi study to investigate this. Check out this new pub here: doi.org/10.1016/j.diab… @CentMedUseSafety Baker Institute Natalie Trevaskis

Outcome-wide cohort study design to identify novel collateral benefits and new indications of SGLT-2 inhibitor Check out this new pub: doi.org/10.1002/cpt.31… CMUS Baker Institute

Over 90% of #frail #nursinghome residents in 🇦🇺🇨🇳🇯🇵🇪🇸 who were most vulnerable to medication #sideeffects were prescribed #medications that may cause harm based on the #STOPPFrail criteria It's time to consider #deprescribing to optimise #medicationuse 🔖bit.ly/frailnh

🧠Our 10-yr pre/post-#Alzheimer's disease study on medication use: bit.ly/medalz 💊While #symptomatic meds plateaued post-diagnosis for both AD & non-AD cohorts, #preventive meds declined in the AD cohort but continued to increase in the non-AD cohort. #deprescribing

Register now for the ASCEPT #Pharmacoepidemiology SIG webinar masterclass with Dr. Jenna Wong on using Machine Learning to Support Activities for Post-Market Drug Safety Surveillance. Sep 17th, 12 pm. Register now: monash.zoom.us/webinar/regist…